U.S. could save $825 million a year with a small change in immunotherapy dosing, study says – STAT
STAT |
U.S. could save $825 million a year with a small change in immunotherapy dosing, study says
STAT That's the finding of a new study on the immunotherapy drug pembrolizumab, marketed commercially as Keytruda by Merck. By switching to weight-based dosing — instead of a fixed dose of 200 mg — doctors could quickly reduce costs of the intravenous … |
